PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.41%
Revenue growth above 1.5x TSM's 6.19%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.96%
Gross profit growth above 1.5x TSM's 6.19%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-19.51%
Negative EBIT growth while TSM is at 148.87%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-19.51%
Negative operating income growth while TSM is at 148.87%. Joel Greenblatt would press for urgent turnaround measures.
-16.72%
Negative net income growth while TSM stands at 38.42%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
-18.75%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-14.34%
Share reduction while TSM is at 15.60%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
2.39%
Diluted share reduction more than 1.5x TSM's 11.51%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
129.66%
OCF growth of 129.66% while TSM is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
392.13%
FCF growth of 392.13% while TSM is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
186.63%
10Y revenue/share CAGR 1.25-1.5x TSM's 149.37%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
186.63%
5Y revenue/share CAGR 1.25-1.5x TSM's 149.37%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
186.63%
3Y revenue/share CAGR above 1.5x TSM's 55.94%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
786.36%
OCF/share CAGR of 786.36% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
786.36%
OCF/share CAGR of 786.36% while TSM is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
786.36%
3Y OCF/share CAGR of 786.36% while TSM is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
246.81%
Positive 10Y CAGR while TSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
246.81%
Positive 5Y CAGR while TSM is negative. John Neff might view this as a strong mid-term relative advantage.
246.81%
Positive short-term CAGR while TSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
410.21%
Equity/share CAGR of 410.21% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
410.21%
Equity/share CAGR of 410.21% while TSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
410.21%
Equity/share CAGR of 410.21% while TSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.49%
Firm’s AR is declining while TSM shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-3.49%
Inventory is declining while TSM stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.43%
Asset growth of 6.43% while TSM is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
33.31%
BV/share growth of 33.31% while TSM is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-0.08%
We’re deleveraging while TSM stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
18.01%
R&D growth of 18.01% while TSM is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
11.29%
SG&A growth of 11.29% while TSM is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.